Back to Trials
NCT06642610NARecruiting

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

Indiana University

Start Date

6/15/2025

Completion Date

6/30/2026

Summary

The primary objective of this pilot study is to develop a CGM-based model to predict the progression from prediabetes to diabetes in individuals with cystic fibrosis.

Eligibility Criteria

Age Range: 12 years to 55 years

Inclusion Criteria: * CF individuals aged 12-55 years. * CF without diabetes or with prediabetes (as defined by OGTT and HbA1c). * Willing to use a continuous glucose monitoring system with compatible smart phone for glucose data collection. A person with CFRD and already using CGM, we will just collect their personal CGM data, and they are not required to have OGTT or HbA1c visit. Exclusion Criteria: * Pregnancy. * History of transplant. * Use of immunosuppressant drugs. * Use of oral steroids or any medication known to interfere with glucose. * Allergy to adhesives. * Individuals with severe concurrent medical conditions that could confound glucose monitoring data (e.g., terminal illness, major organ failure). * Conditions that may make unsafe for participants to do study or impair or confound the study at the discretion of the investigator

Interventions

DEVICE

CGM Dynamic Index (CDI)

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

PrediabetesCystic Fibrosis (CF)Cystic Fibrosis-related Diabetes

Locations

Indiana University Health, University Hospital

Indianapolis, Indiana 46202

United States